
Global R&D Pipeline
My Favorite
Hot Targets:
Muc18
Back
Total number of drugs
13
Phase II and later clinical stages
0%
Involving companies
15
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMT-253 ADC | AMT-253 ADC | Antibody drug conjugate (ADC) ADC | Neoplasms Skin and Musculoskeletal Diseases | Melanoma cell adhesion molecule inhibitors DNA topoisomerase I inhibitors | Multitude Therapeutics, Inc. (China) | Multitude Therapeutics, Inc. (China)Multitude Therapeutics, Inc. | Phase 1/2 | Phase 1/2 | United States | Exatecan 依喜替康 | AMT-253 ADC | IgG - nd | detail > | ||||||||
| 212pb-TCMC-OI-3 | 212pb-TCMC-OI-3 | Radiolabeled antibody Therapeutic radiopharmaceuticals | Neoplasms Respiratory Diseases Other Diseases | Melanoma cell adhesion molecule inhibitors | University of OsloOslo universitetssykehus HFOncoinvent ASA (Old) | Oslo universitetssykehus HFUniversity of OsloOncoinvent ASA (Old) | Preclinical | 212 Pb | 212pb-TCMC-OI-3 | detail > | |||||||||||
| MCAM CAR NK Cells(New York Medical College) | MCAM CAR NK Cells(New York Medical College) | CAR-NK | Neoplasms Skin and Musculoskeletal Diseases Other Diseases | Melanoma cell adhesion molecule inhibitors | Preclinical | MCAM CAR NK Cells(New York Medical College) | detail > | ||||||||||||||
| OI-3 | OI-3 | Monoclonal antibody | Neoplasms | Melanoma cell adhesion molecule inhibitors | Oncoinvent ASA (Old) | Oncoinvent ASA (Old) | Preclinical | OI-3 | detail > | ||||||||||||
| AA-98 | AA-98 | Monoclonal antibody | Neoplasms | Melanoma cell adhesion molecule inhibitors Surface antigens modulators | Chinese Academy of Sciences | Microconstants China | Discovery | Discovery | AA-98 | detail > | |||||||||||
| CN117050186 | CN117050186 | Nanobody | Neoplasms Skin and Musculoskeletal Diseases | First Affiliated Hospital of Shantou University Medical College | First Affiliated Hospital of Shantou University Medical College | Discovery | CN117050186 | detail > | |||||||||||||
| CN117050187 | CN117050187 | Nanobody | Neoplasms Skin and Musculoskeletal Diseases Other Diseases | First Affiliated Hospital of Shantou University Medical College | First Affiliated Hospital of Shantou University Medical College | Discovery | CN117050187 | detail > | |||||||||||||
| Anti-MUC18 monoclonal antibody | Anti-MUC18 monoclonal antibody | Monoclonal antibody | Neoplasms Skin and Musculoskeletal Diseases | Melanoma cell adhesion molecule inhibitors | Abgenix, Inc. | Discontinued | Anti-MUC18 monoclonal antibody | detail > | |||||||||||||
| CD146-ts mAb (Syndivia) | CD146-ts mAb (Syndivia) | Monoclonal antibody | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | Melanoma cell adhesion molecule inhibitors | Syndivia SASSATT PACA Corse SAS | Preclinical | CD146-ts mAb (Syndivia) | detail > | |||||||||||||
| Hu sCD146 (Aix-Marseille Universite) | Hu sCD146 (Aix-Marseille Universite) | Recombinant protein | Cardiovascular Diseases Other Diseases | Fibronectin stimulants integrin subunit beta 4 agonists Melanoma cell adhesion molecule stimulants | Université d'Aix-Marseille | Pending | Hu sCD146 (Aix-Marseille Universite) | detail > |
Total 13 data
1
2


